T cells are the essential effectors of the adaptive immunity. They use their unique receptor, the T cell receptor (TCR), to specifically recognize and respond to antigens associated with the major histocompatibility complex (MHC) molecules. Signal transduction of the TCR is initiated with the function of the CD3 subunits of the TCR complex. The very first event in TCR/CD3 complex activation is the phosphorylation of the cytoplasmic tails of CD3z by the tyrosine kinase Lck, allowing the recruitment of the kinase ZAP70 to phosphorylate a number of downstream mediators and effectors to amplify TCR/CD3 signaling.Adaptor molecules couple the TCR/CD3 complex to a variety of signaling molecules involved in T cell activation and as such play a key role as signal amplifiers. Adaptors include both transmembrane and cytosolic molecules, such as LAT, SLP-76, GRB2, SHC, and Gads. While some adaptor molecules, like TSAd and Nck, may participate in proximal TCR/CD3 signaling by recruiting Lck, other adaptors, such as PAG and SIT, may negatively regulate TCR signaling, thereby contributing to signal termination. Signaling by the TCR has been heavily investigated for exploitation in cancer immunotherapy through approaches involving CAR T cells or other engineered T cells. Adaptor proteins have fundamental roles in the finetuning the tightly controlled intricate process of TCR/CD3 signaling both in T cell homeostasis and immune responses. Harnessing their signal modulating properties may help develop better cancer immunotherapies. Additionally, adaptor molecules are among the components of the TCR signaling cascade being investigated for their implication in pathological conditions including autoimmunity and hematologic malignancies, and some adaptor molecules have been identified as therapeutic targets to treat or alleviate those conditions. This Research Topic focuses on adaptor proteins that participate in T cell signaling and thus modulate the adaptive immune response.Luff et al. ( 1) have documented the indispensable role of phosphoinositide 3-kinase d (PI3Kd) that is recruited to and activated at the TCR signalosome. Using mass spectrometry, biochemical approaches and CRIPR gene editing, they demonstrated that PI3Kd interacts with many adaptor proteins involved in naïve T cell activation and proliferation. Importantly, these novel interactions between PI3Kd and adaptor proteins occurring in T cells may be Frontiers in Immunology frontiersin.org 01